Free Trial

Danaher Corporation $DHR Shares Sold by BigSur Wealth Management LLC

Danaher logo with Medical background

Key Points

  • BigSur Wealth Management LLC has reduced its stake in Danaher Corporation by 16.1%, now holding 12,315 shares valued at approximately $2.4 million.
  • Danaher has received positive ratings from analysts, with 17 out of 20 analysts rating it as a "Buy" and an average price target of $245.91.
  • The company recently declared a quarterly dividend of $0.32 per share, with an annual yield of 0.7%, which will be paid on October 31st.
  • Interested in Danaher? Here are five stocks we like better.

BigSur Wealth Management LLC lowered its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 16.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,315 shares of the conglomerate's stock after selling 2,360 shares during the period. BigSur Wealth Management LLC's holdings in Danaher were worth $2,437,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. GHP Investment Advisors Inc. boosted its holdings in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of Danaher during the 4th quarter valued at approximately $27,000. Sierra Ocean LLC lifted its holdings in Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new position in Danaher in the first quarter worth approximately $31,000. Finally, Dunhill Financial LLC increased its stake in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after acquiring an additional 67 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Guggenheim reiterated a "buy" rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. UBS Group decreased their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Robert W. Baird lifted their target price on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Finally, Bank of America decreased their price target on Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research note on Monday. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $245.91.

Read Our Latest Stock Analysis on DHR

Danaher Trading Down 2.0%

NYSE:DHR opened at $185.90 on Thursday. The firm has a market cap of $133.11 billion, a PE ratio of 39.55, a price-to-earnings-growth ratio of 2.70 and a beta of 0.75. The stock has a fifty day moving average price of $199.80 and a 200 day moving average price of $197.89. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher's revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 11.10% of the company's stock.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.